| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
-Deficient Mice
Lilly Research Laboratories, Eli Lilly, Indianapolis, IN 46285
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
(PKC) serine/threonine kinase has been implicated in signaling of T cell activation, proliferation, and cytokine production. However, the in vivo consequences of ablation of PKC on T cell function in inflammatory autoimmune disease have not been thoroughly examined. In this study we used PKC-deficient mice to investigate the potential involvement of PKC in the development of experimental autoimmune encephalomyelitis, a prototypic T cell-mediated autoimmune disease model of the CNS. We found that PKC–/– mice immunized with the myelin oligodendrocyte glycoprotein (MOG) peptide MOG35–55 were completely resistant to the development of clinical experimental autoimmune encephalomyelitis compared with wild-type control mice. Flow cytometric and histopathological analysis of the CNS revealed profound reduction of both T cell and macrophage infiltration and demyelination. Ex vivo MOG35–55 stimulation of splenic T lymphocytes from immunized PKC–/– mice revealed significantly reduced production of the Th1 cytokine IFN-
as well as the T cell effector cytokine IL-17 despite comparable levels of IL-2 and IL-4 and similar cell proliferative responses. Furthermore, IL-17 expression was dramatically reduced in the CNS of PKC–/– mice compared with wild-type mice during the disease course. In addition, PKC–/– T cells failed to up-regulate LFA-1 expression in response to TCR activation, and LFA-1 expression was also significantly reduced in the spleens of MOG35–55-immunized PKC–/– mice as well as in in vitro-stimulated CD4+ T cells compared with wild-type mice. These results underscore the importance of PKC in the regulation of multiple T cell functions necessary for the development of autoimmune disease. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
(PKC)2 is unique among other PKC members because it colocalizes with the TCR in the T cell immunological synapse (2, 3, 4). In cultured cell lines, PKC-mediated signal transduction has been shown to result in activation of the transcription factors, AP-1 and NF-
B, in response to TCR/CD28 costimulation, ultimately culminating in the induction of expression of genes that are essential for the proliferation and function of activated T cells (5, 6, 7, 8). The physiological functions of PKC for TCR signaling were subsequently demonstrated by two independent studies with PKC-deficient mice (9, 10). Peripheral T cells of PKC–/– mice show reduced proliferation and IL-2 production and significant impairment in AP-1 and NF-B (9, 10) as well as NFAT (10) activation in response to TCR/CD28 stimulation. Although numerous studies have implicated the IB
kinase IKK complex in linking PKC to NF-B activation (5, 6, 7, 8), the pathway responsible for coupling PKC to AP-1 appears to be JNK independent (9). Recently, a study has identified the stress-related STE20/SPS1-like, proline alanine-rich kinase, SPAK, as a substrate and target of PKC in a TCR/CD28-induced signaling pathway leading to selective activation of AP-1, but not NF-B (11).
Naive CD4+ T cells can develop into either Th1 or Th2 effector cells as well as a distinct IL-17-secreting T effector cell type (12) upon activation, depending on the cytokines present and the quality and magnitude of both T cell and costimulatory receptor signaling (13, 14, 15, 16, 17). Recent studies provide some evidence that PKC is involved not only in T cell activation, but also in Th1/Th2 differentiation under different inflammatory conditions in vivo (18, 19). However, little is known about the role of PKC in T cell production of IL-17 and Th17 differentiation. In an asthmatic lung inflammation model, Th2 immune responses were preferentially impaired in the absence of PKC without a profound defect in Th1 responses in lung, even though PKC was required for the initial development of Th1 cells (18). Furthermore, PKC–/– mice were able to mount a normal protective Th1 response against Leishmania major infection, but not a Th2 response to Nippostrongylus brasiliensis (19), indicating that PKC preferentially modulates Th2 immune responses. However, it is not clear whether PKC plays any role in autoimmune disease conditions in which Th1/IL-17 responses predominate. We therefore investigated the effects of ablation of PKC in the myelin oligodendrocyte glycoprotein (MOG)35–55-induced mouse experimental autoimmune encephalomyelitis (EAE) model. We found that PKC–/– mice were completely resistant to the induction of EAE and exhibited profound reduction of infiltrating inflammatory cells and demyelination in the CNS compared with wild-type (WT) mice. Consistent with these observations, PKC–/– CD4+ T cells failed to up-regulate surface expression of LFA-1 upon activation in vitro, and LFA-1 expression was also significantly reduced in the spleens of MOG35–55-immunized PKC–/– mice compared with WT mice. Furthermore, splenocytes from immunized PKC–/– mice produced significantly lower levels of the Th1 cytokine, IFN-, as well as IL-17 upon ex vivo Ag restimulation compared with WT mice. The generation of Ag-specific IL-17-producing cells ex vivo was profoundly impaired in MOG35–55-immunized PKC–/– mice. In contrast, production of the Th2 cytokine, IL-4, was marginally affected in PKC–/– under similar conditions. Taken together, these results suggest that PKC plays an essential role in the regulation of autoimmune effector T cells involved in the immunopathology of EAE and is a potential therapeutic target for treating T cell-mediated autoimmune diseases.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
PKC-deficient mice were described previously (9). PKC–/– mice were backcrossed onto C57BL/6 > 11 times. Both PKC–/– mice and WT littermate breeding colonies were established and maintained at Taconic Farms. All animal experimental procedures used in this study were approved by the Eli Lilly animal care and use committee and were conducted in accordance with the guidelines of Eli Lilly.
Induction and clinical evaluation of MOG35–55-induced EAE
All mice were age and sex matched (6- to 10-wk-old females) at the start of the experiments, and WT littermates were used as controls. PKC–/– and WT mice were immunized s.c. at two sites on the back with 300 µg of MOG35–55 (MEVGWYRSPFSRVVHLYRNGK; Peptides International), emulsified in a total of 200 µl of CFA (Difco) containing 500 µg of Mycobacterium tuberculosis H37 Ra (Difco) on days 0 and 7, and supplemented with i.p. injections of 500 ng of pertussis toxin (Calbiochem) on days 0 and 2. Clinical symptoms of EAE were scored daily by two separate observers using the following scale: 0, no symptoms; 0.5, distal weak or spastic tail; 1, completely limp tail; 1.5, limp tail and hind limb weakness (feet slip through cage grill); 2.0, unilateral partial hind limb paralysis; 2.5, bilateral partial hind limb paralysis; 3.0, complete bilateral hind limb paralysis; 3.5, complete hind limb and unilateral partial forelimb paralysis; and 4.0, moribund or death. The data were recorded as the mean daily clinical score.
Histology and immunohistochemistry
MOG35–55-immunized PKC–/– and WT mice were killed on days 21–25, and spinal cords were removed, fixed overnight in IHC zinc fixative (BD Pharmingen), solution and transferred to 70% ethanol before processing through paraffin. Five- to 7-µm sections were generated by microtome, and sections were placed on positively charged slides. Slides were baked overnight at 60°C, deparaffinized in xylene, and rehydrated through graded alcohols to water. Rehydrated tissue sections were immersed in Luxol Fast Blue (0.1% alcoholic; Poly Scientific R&D) solution at 56°C for 24 h, followed by washing with distilled water, differentiation with 0.05% lithium carbonate, then counterstained with Cresyl Echt Violet (0.1% aqueous), and dehydrated through graded alcohols before permanent mounting.
For immunohistochemical staining, sections were deparaffinized, rehydrated, and quenched for endogenous peroxidase activity with 1% H2O2, 0.1% Triton X-100, then blocked with 15% normal rabbit serum. Endogenous biotin was blocked with an avidin/biotin blocking kit (Vector Laboratories). Sections were incubated overnight at 4°C with primary Ab at an optimal concentration prepared in Ab diluent (DakoCytomation). Slides were then incubated with biotinylated rabbit anti-rat IgG (Vector Laboratories). For CD45 (Serotec) and I-A/I-E (BD Pharmingen) staining, sections were processed with the ABC Elite-HRP complex (Vector Laboratories). For CD4 (Serotec) and CD11b (Serotec) staining, sections were incubated with streptavidin-HRP and amplified with thymic shared Ag, followed by incubation with streptavidin-HRP. Color development was performed using the 3,3'-diaminobenzidine substrate kit for peroxidase (Vector Laboratories) according to the kit protocol. All wash steps between incubations were with TBS with 0.5% Tween 20. Slides were counterstained with nuclear fast red (Vector Laboratories), dehydrated, and mounted with Clearium (Surgipath). For the negative control, equivalent concentrations of rat isotype control IgG2b (Serotec) were used to replace the primary Ab and were processed according to the above-described protocol.
Flow cytometric analysis
CD4+ T cells were purified from splenocytes of both WT and PKC–/– mice using magnetic beads according to the manufacturer’s instructions (Miltenyi Biotec). CD4+ T cells (1 x 106/ml) were activated in 96-well plates that had been precoated with 1 µg/ml anti-CD3 Ab (BD Pharmingen) for the indicated time. For analysis of spinal cord mononuclear cell infiltrates, mononuclear cells from the spinal cords of the mice that were at the peak of disease (day 21) were isolated by Percoll gradient centrifugation. Briefly, pooled spinal cords were dissociated by glass homogenization in ice-cold GKN buffer (8.00 g/l NaCl, 0.40 g/l KCl, 3.56 g/l Na2HPO4·12H2O, 0.78 g/l NaH2PO4·2H2O, and 2 g/l D-(+)-glucose (pH 7.4)) with 0.02% BSA. Dissociated tissues were washed once in GKN/BSA and enzymatically digested for 30 min at 37°C with 250 µg/ml type II collagenase (Sigma-Aldrich). The digested spinal cord preparation was passed through a 40-µm-pore-size cell strainer, washed once with GKN/BSA, and resuspended in 30% isotonic Percoll (Pharmacia Biotech). The suspension was fractionated with a 30/37/70% Percoll gradient by centrifugation at 500 x g for 30 min at 25°C. Cells were collected from the 37/70% interface and washed with PBS containing 2% FCS and 0.1% BSA.
All flow cytometric data were collected and analyzed with a Cytomics FC500 (Beckman Coulter) using RXP software (Becton Coulter). The following staining Abs were purchased from BD Pharmingen: anti-ICAM-1 (3E2), anti-CD45-CyC (20-F1), anti-CD4-PE (L3T4), anti-CD8a-FITC (53-6.7), and isotype control Abs (rat IgG-FITC and rat IgG-PE). Anti-ICOS-1 (7E.17G9), anti-CD11a-PE (2D7), CD11b-PE (M1/70), and anti-CD49d-PE (PS2) were purchased from Biolegend. F4/80-FITC (MCA497F) was purchased from Serotec.
Splenocyte cell culture and proliferation assay
Splenocyte cell suspensions were isolated from MOG35–55-immunized WT and PKC–/– mice on days 14 and 21, along with naive WT mice, by homogenizing spleens between frosted glass slides (Fisher Scientific) and removing RBC with buffered ammonium chloride lysing buffer (BioWhittaker). Pooled splenocytes of five individual mice from the same group were plated in triplicate in 96-well, round-bottom plates at 2 x 105 cells/well in 200 µl of complete RPMI 1640 medium (Invitrogen Life Technologies) supplemented with 2 mM L-glutamine, 25 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin, 5.5 x 10–5 M 2-ME, and 5% FCS (all supplements from Invitrogen Life Technologies) containing 0–50 µg/ml MOG35–55 (Peptides International) and cultured at 37°C in 5% CO2. Proliferation was measured by incorporation of [3H]methylthymidine (1 µCi/well; ICN Radiochemicals) during the last 8 h of culture using a Filtermate harvester (Packard Instruments) and a 1450 Microbeta liquid scintillation counter (Pharmacia Biotech).
ELISA and ELISPOT analyses
Cytokine levels produced by cultured splenocytes from MOG35–55-immunized PKC–/– and WT mice along with naive WT spleens were analyzed by removing 100 µl of cell culture supernatant/well after 72 h of culture as described above. Supernatants were filtered using Millipore plates (Mabvnob) and stored at –80°C. Cytokines were analyzed with an R&D Systems MAP Kit (LUM000) with the following beads: IL-2 (CLUM402), IFN- (LUM485), IL-4 (LUM404), and IL-17 (M1700).
The quantitative determination of the frequency of cells releasing mouse IL-17 was performed using R&D Systems mouse IL-17 ELISPOT (EL421). Briefly, freshly isolated spleen cells from immunized WT and PKC–/– mice were plated in HL-1/1% glutamine-supplemented medium at 1 x 106 cells/well (100 µl/well) with or without MOG35–55 at 0, 5, and 50 µg/ml. The plates were incubated at 37°C in a 5% CO2 incubator for 72 h and developed according to the manufacturer’s recommended protocol. The number of specific spots was counted with an ImmunoSpot analyzer (Cellular Technology).
TaqMan quantitative RT-PCR analysis
Total cellular RNA pooled from spinal cords of WT or PKC–/– mice on day 21 was prepared using a RNeasy Mini Kit (Qiagen), DNase treated, and quantified by spectrophotometric analysis. A two-step quantitative RT-PCR was performed to determine IL-17 and LFA-1 expression using the relative standard curve method, with the cellular housekeeping enzyme GAPDH as the normalization control. cDNA was synthesized with a High Capacity cDNA Archive Kit (ABI 4322171; Applied Biosystems) using GeneAmp PCR 9700 (Applied Biosystems). A second PCR step was performed using TaqMan Universal PCR Master Mix (ABI 4304437) and the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). IL-17 Assay-on-Demand TaqMan Gene Expression (ABI Mm00439619_m1), LFA-1 (ABI Mm00801807_m1), and GAPDH primers and probe (4352339E; Applied Biosystems) were used. For quantification and normalization to GAPDH, standard curves were generated for IL-17, LFA-1, and GAPDH using serially diluted cDNA samples from WT spinal cords. Threshold cycle numbers were determined with Sequence Detector software (version 2.1.1; Applied Biosystems) and transformed using a standard curve generated from serially diluted cDNA samples from WT spinal cords as a reference. The amounts of IL-17 and LFA-1 were divided by the GAPDH amount to obtain a normalized target value.
Statistical analysis
Comparison of clinical scores and cytokine production levels between the various treatment groups were analyzed by unpaired Student’s t test. A value of p < 0.01 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
-deficient mice are resistant to induction of MOG35–55-induced EAE
To investigate the role of PKC in the development of autoimmune T cell responses and disease induction, we immunized WT and PKC–/– mice with MOG35–55 peptide to induce EAE. As depicted in Fig. 1, the disease onset in WT mice occurred around days 13–14 and peaked between days 21 and 30, with a mean maximum disease score of 2.2. In contrast, PKC–/– mice were completely resistant to EAE induction. WT or PKC–/– mice immunized with CFA alone did not display EAE signs (data not shown). These results show that PKC is necessary for the induction of MOG35–55-induced EAE in mice.
|
-deficient mice after EAE induction
EAE is characterized by inflammatory cell infiltration into tissues of the CNS (20). To determine whether resistance to EAE induction in PKC–/– mice was associated with a reduction of CNS inflammation, we next examined leukocyte infiltration and demyelination in the spinal cords of WT and PKC–/– mice by both immunohistochemical staining and flow cytometric analysis of spinal cords at the peak of disease (on day 21). As shown in Fig. 2, spinal cords from PKC–/– mice did not show visible signs of demyelinating lesions, as revealed by Luxol Fast Blue staining (Fig. 2B), or cellular infiltrates by CD45-positive staining (Fig. 2D), consistent with the clinical EAE scores. In contrast, WT mice showed extensive demyelination (Fig. 2A), closely associated with heavy leukocyte infiltration (Fig. 2C) into the spinal cord parenchyma. These results suggest that the resistance of PKC–/– mice to MOG35–55-induced EAE is primarily due to the reduction of mononuclear cell infiltration and the absence of demyelination in CNS during EAE induction.
|
–/– mice. Mononuclear cells isolated from the spinal cords of PKC–/– and WT mice harvested on day 21 were stained for CD45 and CD4 or CD11b and analyzed by flow cytometry. As shown in Fig. 3A, there was a profound reduction in the percentage of infiltration of T cells (CD45highCD4+) as well as macrophages (CD45+CD11b+) in the spinal cords of PKC–/– mice (right panels) compared with WT mice. The diminished infiltration of CD4+ T cells and CD11b+ macrophages was confirmed by immunohistochemical staining of the spinal cords of PKC–/– mice (Fig. 3B). These results support the idea that the lack of PKC leads to reduction of mononuclear cell infiltration into the CNS and spinal cord demyelination during EAE progression.
|
production in PKC–/– splenocyte cultures
To determine whether resistance of EAE induction in PKC–/– mice was simply due to a reduced response of T cells to immunized Ag or to an impairment in T cell effector and proliferative functions, we examined cytokine production and T cell proliferation from MOG35–55-immunized PKC–/– or WT splenocytes on day 14 (onset of the disease) or 21 (peak of the disease) upon ex vivo stimulation in the presence of different concentrations of MOG35–55 peptide. Compared with WT animals, splenocytes from PKC–/– mice produced significantly less IFN- in response to MOG35–55 stimulation at all MOG35–55 concentrations tested at both stages of the disease (Fig. 4A). In contrast, IL-2 production by PKC–/– cells was only slightly decreased in comparison with WT cells on day 14 and was not different from WT on day 21 (Fig. 4B). Similar to IL-2 production, the Th2 cytokine, IL-4, was slightly lower in PKC–/– splenocytes compared with WT on day 14, but levels were comparable or slightly higher on day 21 (Fig. 4C). Collectively, these data suggest that PKC was important for optimal T cell responses, including Th2 cytokine production at initial Ag encounter. For Th1 IFN- production, PKC remained an essential signaling factor at both early and late time points.
|
–/– splenocytes were slightly lower than WT responses on day 14 (Fig. 4D), which was consistent with lowered IL-2 secretion compared with WT (Fig. 4B). These effects were significant. However, there was no significant difference in MOG35–55-stimulated proliferation between WT and PKC–/– splenocytes on day 21 after immunization (Fig. 4D), which is in agreement with the equivalent levels of IL-2 secretion (Fig. 4B). Thus, PKC–/– T cells were efficiently primed with MOG35–55 immunization.
PKC is necessary for IL-17 production in spleen and CNS
We next examined the levels of the proinflammatory cytokine, IL-17, which is produced by a subset of IL-23-driven Th cells and is important for the development of EAE (12). As shown in Fig. 5A, IL-17 was reduced >50% in splenocyte culture from PKC–/– mice compared with WT mice on days 14 and 21, suggesting that PKC is important for the generation of this pathogenic cytokine.
|
–/– may regulate IL-17 production, we determined the number of IL-17-secreting cells from MOG35–55-immunized PKC–/– or WT splenocytes on day 21 upon ex vivo stimulation in the presence of the indicated concentrations of MOG35–55 peptide (Fig. 5B). The frequency of Ag-specific IL-17-producing cells in the spleen after MOG restimulation was significantly reduced in PKC–/– splenocytes compared with WT spleen. In contrast, there was no significant difference in IL-17 synthesis upon OVA stimulation, suggesting that the reduction in IL-17 production may be Ag specific.
In addition, spleen cell cultures from PKC–/– mice produced significantly less IL-17 in response to IL-23 stimulation in vitro (Fig. 5C), indicating that PKC may play a role in IL-23-induced Th17 polarization. To put the relevance of these observations within the context of EAE resistance, we examined potential differences in IL-17 expression in the CNS of PKC–/– and WT mice. Consistent with the pathogenic role of IL-17 in EAE, quantitative TaqMan RT-PCR analysis revealed a 6-fold reduction in IL-17 expression in the spinal cords of PKC–/– mice compared with WT mice at the peak of the disease (Fig. 5D).
Reduced LFA-1 expression in PKC–/– CD4+ T cells and spleens
As shown in Figs. 2 and 3, there was strikingly less mononuclear cell infiltration in the CNS of PKC–/– mice compared with WT mice. We therefore measured the surface expression of the major integrins known to be involved in activated pathogenic T cell migration into the CNS during EAE development. Purified CD4+ T cells of naive PKC–/– and WT mice were stained for various surface markers before (Fig. 6, A and B) and after (Fig. 6, C and D) stimulation with anti-CD3 and were subsequently analyzed by flow cytometry (Fig. 6). Anti-CD3 stimulation of WT cells resulted in an increased number of cells with high surface expression of LFA-1 (Fig. 6, A and C, LFA-1, dashed line histograms). In contrast, PKC–/– T cell cultures failed to up-regulate LFA-1 surface expression after treatment with anti-CD3 (solid line histograms). Importantly, the reduced LFA-1 surface expression on PKC–/– CD4+ T cells appeared to be specific, because the surface expression of ICOS-1 (21) before or after T cell activation did not change appreciably under the same conditions (Fig. 6, B and D). The dependence of LFA-1 up-regulation on PKC was substantiated by quantitative TaqMan RT-PCR analysis of the spleens from MOG35–55-immunized PKC–/– mice and WT mice (Fig. 6E). Thus, the decreased expression of LFA-1 may at least partly account for the markedly reduced leukocyte infiltration into the CNS of PKC–/– mice during EAE development.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
is crucial for signaling events leading to activation, proliferation, and cytokine production of mature T cells (9, 10). The role of PKC in T cell differentiation and function in inflammatory diseases is less clear. For example, the induction of an immune response to viral infections is not impaired in the absence of PKC (22, 23, 24). Interestingly, PKC has been shown to be critical for Th2 inflammatory responses in vivo after respiratory challenge with OVA (18) and N. brasiliensis infection (19), but is dispensable for Th1 responses. Therefore, the role of PKC in T cell differentiation may depend on the specific Ag(s) and organs. In this study we examined the role of PKC in the Th1/IL-17 effector T cell-dependent MOG35–55-induced EAE model using PKC–/– mice. We found that PKC–/– mice were remarkably resistant to the induction of EAE immunized by MOG35–55. Consistent with this observation, there were profound reductions in leukocyte infiltration into the CNS, including CD4+ T cells and macrophages, in PKC–/– mice compared with WT (Figs. 2 and 3). Furthermore, the Th1 cytokine, IFN- (Fig. 4A), and the proinflammatory/pathogenic cytokine, IL-17 (Fig. 5), were diminished significantly upon Ag stimulation ex vivo in PKC–/– cells from postimmunized mice on both days 14 and 21.
In contrast, the levels of the Th2 cytokine, IL-4, were not affected or were higher in PKC–/– splenocyte culture compared with WT, with slightly lower levels in the PKC–/– splenocyte culture on day 14 after immunization, which could be due to the reduced cell proliferation (Fig. 4D). Our data suggest that PKC plays an essential role in the development of autoimmune Th1 (IFN-) responses as well as in the production of the key pathogenic cytokine, IL-17, in vivo.
Previous studies have demonstrated that T cell proliferation is impaired in the absence of PKC upon anti-CD3 stimulation in vitro (9, 10). We also observed a small, but significant, impairment of T cell proliferative responses upon MOG35–55 stimulation on day 14, but not day 21, after immunization (Fig. 4D). In our study, splenocytes from both WT and PKC were able to produce comparable levels of IL-2 in response to MOG35–55, especially on day 21 (Fig. 4B). This is also different from previous results that showed a marked decrease in anti-CD3-stimulated IL-2 production in the absence of PKC (9, 10). Addition of exogenous rIL-2 can rescue anti-CD3-dependent T cell proliferation, suggesting that diminished IL-2 production is primarily responsible for the defect in T cell proliferation (9). The different outcomes of MOG35–55 and anti-CD3 stimulation of T cells could be due to the fact that anti-CD3 stimulation acts mainly on naive T cells, whereas MOG35–55 stimulation operates through previously Ag-primed T cells.
Autoreactive IL-17-producing Th cells are highly potent at inducing CNS immune pathology, and adoptive transfer of IL-17-producing CD4+ T cells into recipient mice efficiently induces EAE (12). Such IL-17-producing CD4+ T cells appear to emerge from previously activated Th cells in the presence of IL-23 (12). Furthermore, administration of neutralizing IL-17 mAb results in partial protection of EAE induction, suggesting that IL-17 is one of the key cytokines in the pathogenesis of EAE (12). Consistent with its critical role in EAE pathogenesis, we found that IL-17 production from MOG35–55-activated primed splenocytes from PKC–/– mice was significantly reduced compared with that in WT mice (Fig. 5A). PKC–/– mice showed a profound reduction of IL-17 synthesis per cell upon MOG35–55 stimulation ex vivo, but no difference in IL-17 synthesis upon OVA stimulation (Fig. 5B), suggesting that the defect in IL-17 production may be Ag specific. Indeed, IL-17 expression was markedly reduced in the CNS of immunized PKC–/– mice (Fig. 5D). This could be due to a reduction in the number of differentiated and/or survival of IL-17-producing Th cells as well as IL-17 expression at the mRNA level. With respect to the latter, a crucial role for NFAT, a downstream effector of PKC (10), in TCR-mediated regulation of IL-17 gene transcription has been demonstrated (25). However, we have not ruled out the possible role of PKC in IL-23-mediated IL-17 synthesis in the development of EAE, and our data support this concept (Fig. 5C).
The reduced IL-17 production by PKC-deficient T cells may only partially account for the resistance to EAE induction, because administration of neutralizing IL-17 mAb produced only partial inhibition of EAE in mice, suggesting that other factors contribute to EAE in mice (12). Cell traffic may also be a key factor. T cell transendothelial adhesion is mediated by two major integrins, LFA-1 (CD11a), interacting with ligands ICAM-1/ICAM-2/ICAM-3, and VLA-4, interacting principally with VCAM-1 (26). LFA-1-mediated transendothelial migration of encephalitogenic T cells has been suggested to be involved in the pathogenesis of EAE (27). Furthermore, leukocytes from patients with multiple sclerosis were found to display significantly higher adhesion capacity and expressed higher levels of LFA-1, suggesting that LFA-1/ICAM interactions may promote the adherence of leukocytes to brain microvascular endothelial cells, contributing to the disease pathology (28, 29). Thus, our findings that PKC–/– mice had reduced ability to up-regulate LFA-1 cell surface expression on CD4+ T cells upon activation (Fig. 6A) and decreased expression of LFA-1 in their spleens during the disease course (Fig. 6B) may explain, at least in part, the markedly reduced leukocyte infiltration into the CNS. In support of this view, anti-LFA-1 Abs have been shown to block completely the induction of EAE (30, 31). Down-modulation of LFA-1 (and VLA-4) was found recently to correlate with clinical responses to IFN-
treatment in patients with relapsing-remitting multiple sclerosis (32), and similar mechanisms were demonstrated in rat EAE upon treatment with lovastatin (33), which apparently is an inhibitor of the LFA-1/ICAM-1 interaction (34). Surface expression of VLA-4 was not differentially regulated between WT and PKC–/– T cells (data not shown), suggesting that LFA-1 and VLA-4 may have nonredundant roles in mediating pathogenic T cells infiltrating the CNS during EAE development.
It is possible that PKC deficiency may also affect the expression of chemokines and/or chemokine receptors, which may contribute to the lack of infiltrating T cells in the CNS. Furthermore, we have not ruled out the possibility that PKC deficiency may render T cells more prone to apoptosis in vivo, given that PKC has been reported to protect T cells from Fas-induced apoptosis via phosphorylation and inactivation of pro-apoptotic protein BAD (35, 36). It would not be surprising if the cumulative impact of multiple defects in T cell functions were ultimately responsible for the profound resistance of PKC–/– mice to EAE. Although future studies will be necessary to test these hypotheses to determine the exact mechanism(s) by which PKC regulates the development of EAE, our data clearly show that PKC modulates both Th1 and Th17 cytokine profiles, affects processes necessary for leukocyte infiltration into the CNS, and collectively plays an important role in the development of EAE. Thus, PKC may serve as an attractive therapeutic target for treating autoimmune diseases such as multiple sclerosis.
Note added in proof.
While this paper was under review, similar findings were reported by Salek-Ardakani et al. (37).
|
Acknowledgments |
|---|
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Footnotes |
|---|
1 Address correspondence and reprint requests to Dr. Subba R. Chintalacharuvu, Lilly Research Laboratories, Eli Lilly, Indianapolis, IN 46285; E-mail address: chinne{at}lilly.com or Dr. Songqing Na, Lilly Research Laboratories, Eli Lilly, Indianapolis, IN 46285; E-mail address: na_s{at}lilly.com 
2 Abbreviations used in this paper: PKC, protein kinase C; MOG, myelin oligodendrocyte glycoprotein; EAE, experimental autoimmune encephalomyelitis; WT, wild type.
Received for publication May 12, 2005. Accepted for publication December 13, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
: signaling from the center of the T-cell synapse. Curr. Opin. Immunol. 14: 323-330. [Medline] in T cell activation. Annu. Rev. Immunol. 20: 761-794. [Medline] isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes. Mol. Cell. Biol. 16: 1842-1850. [Abstract] participates in NF-B activation induced by CD3-CD28 costimulation through selective activation of IB kinase . Mol. Cell. Biol. 20: 2933-2940. B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-. Proc. Natl. Acad. Sci. USA 97: 3394-3399. demonstrates cell-type selective function. Eur. J. Immunol. 30: 3645-3654. [Medline] is required for TCR-induced NF-B activation in mature but not immature T lymphocytes. Nature 404: 402-407. [Medline] affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J. Exp. Med. 197: 1525-1535. in T-cell receptor-induced AP-1 activation pathway. EMBO J. 23: 1112-1122. [Medline]-transgenic model. J. Exp. Med. 182: 1579-1584. . J. Immunol. 173: 6440-6447. is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J. Exp. Med. 200: 181-189. signals activation versus tolerance in vivo. J. Exp. Med. 199: 743-752. during in vivo CD8+ T cell effector and memory responses. Proc. Natl. Acad. Sci. USA 102: 14374-14379. is not essential for T-cell-mediated clearance of murine gammaherpesvirus 68. J. Virol. 79: 6808-6813. 2 integrin LFA-1 in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55: 1060-1072. [Medline] treatment. J. Neuroimmunol. 150: 123-131. [Medline] and 
promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD. J. Biol. Chem. 275: 37246-37250. mediates a selective T cell survival signal via phosphorylation of BAD. J. Immunol. 166: 5955-5963. controls Th1 cells in experimental autoimmune encephalomyelitis. J. Immunol. 175: 7635-7641. This article has been cited by other articles:
|
|
 |
|
  K. A. Staschke, S. Dong, J. Saha, J. Zhao, N. A. Brooks, D. L. Hepburn, J. Xia, M. F. Gulen, Z. Kang, C. Z. Altuntas, et al. IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated Disease J. Immunol., July 1, 2009; 183(1): 568 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Gruber, N. Hermann-Kleiter, R. Hinterleitner, F. Fresser, R. Schneider, G. Gastl, J. M. Penninger, and G. Baier PKC-{theta} Modulates the Strength of T Cell Responses by Targeting Cbl-b for Ubiquitination and Degradation Sci. Signal., June 23, 2009; 2(76): ra30 - ra30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Letschka, V. Kollmann, C. Pfeifhofer-Obermair, C. Lutz-Nicoladoni, G. J. Obermair, F. Fresser, M. Leitges, N. Hermann-Kleiter, S. Kaminski, and G. Baier PKC-{theta} selectively controls the adhesion-stimulating molecule Rap1 Blood, December 1, 2008; 112(12): 4617 - 4627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Manicassamy, D. Yin, Z. Zhang, L. L. Molinero, M.-L. Alegre, and Z. Sun A Critical Role for Protein Kinase C-{theta}-Mediated T Cell Survival in Cardiac Allograft Rejection J. Immunol., July 1, 2008; 181(1): 513 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sakowicz-Burkiewicz, G. Nishanth, U. Helmuth, K. Drogemuller, D. H. Busch, O. Utermohlen, M. Naumann, M. Deckert, and D. Schluter Protein Kinase C-{theta} Critically Regulates the Proliferation and Survival of Pathogen-Specific T Cells in Murine Listeriosis J. Immunol., April 15, 2008; 180(8): 5601 - 5612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jurynczyk, A. Jurewicz, C. S. Raine, and K. Selmaj Notch3 Inhibition in Myelin-Reactive T Cells Down-Regulates Protein Kinase C{theta} and Attenuates Experimental Autoimmune Encephalomyelitis J. Immunol., February 15, 2008; 180(4): 2634 - 2640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Marsland, C. Nembrini, K. Grun, R. Reissmann, M. Kurrer, C. Leipner, and M. Kopf TLR Ligands Act Directly upon T Cells to Restore Proliferation in the Absence of Protein Kinase C-{theta} Signaling and Promote Autoimmune Myocarditis J. Immunol., March 15, 2007; 178(6): 3466 - 3473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Manicassamy and Z. Sun The Critical Role of Protein Kinase C-{theta} in Fas/Fas Ligand-Mediated Apoptosis J. Immunol., January 1, 2007; 178(1): 312 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kaushansky, M.-C. Zhong, N. Kerlero de Rosbo, R. Hoeftberger, H. Lassmann, and A. Ben-Nun Epitope Specificity of Autoreactive T and B Cells Associated with Experimental Autoimmune Encephalomyelitis and Optic Neuritis Induced by Oligodendrocyte-Specific Protein in SJL/J Mice J. Immunol., November 15, 2006; 177(10): 7364 - 7376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Healy, E. Izmailova, M. Fitzgerald, R. Walker, M. Hattersley, M. Silva, E. Siebert, J. Terkelsen, D. Picarella, M. D. Pickard, et al. PKC-{theta}-Deficient Mice Are Protected from Th1-Dependent Antigen-Induced Arthritis J. Immunol., August 1, 2006; 177(3): 1886 - 1893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sutton, C. Brereton, B. Keogh, K. H.G. Mills, and E. C. Lavelle A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis J. Exp. Med., July 10, 2006; 203(7): 1685 - 1691. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
